Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brivanib · 1 trial · 1 indication
Defined as the percentage of patients with complete response, partial response, or stable disease at 12 weeks from randomization by RECIST v1.1.
Defined as the time from random assignment to radiologic disease progression.
| Arm | Type | Description |
|---|---|---|
| Brivanib 800 mg, QD + BSC | EXPERIMENTAL | - |
| Brivanib 400 mg, BID + BSC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Brivanib 800 mg, QD | DRUG | Brivanib Alaninate 800 mg QD, PO |
| Brivanib 400 mg, BID | DRUG | Brivanib Alaninate 400 mg BID, PO |
Inclusion Criteria: * 18-75 years, male or female * Histologically or cytologically confirmed or the clinical diagnosis standard confirmed hepatocellular carcinoma (HCC) patients * Failure or intolerance to prior treatment with chemotherapy and/or targeted therapy * Liver function status Child-Pugh...
Brivanib is an investigational small molecule kinase inhibitor being developed by Zai Lab Limited for hepatocellular carcinoma (HCC), the most common form of primary liver cancer. It is a Phase 2 oral agent studied in Chinese patients with previously treated advanced HCC. Brivanib is also referred to as Brivanib 800 mg, QD.
Brivanib is being studied for hepatocellular carcinoma (HCC), specifically in patients with advanced disease who have already received prior treatment. The clinical program has focused on Chinese patients with previously treated advanced HCC. It remains investigational and is not an approved therapy for HCC.
Brivanib targets the vascular endothelial growth factor receptors FLT1, FLT4 and KDR, along with the fibroblast growth factor receptors FGFR1, FGFR3 and FGFR4. As an inhibitor of these receptor kinases, it is designed to block VEGF- and FGF-driven signaling pathways involved in tumor growth and angiogenesis.
Brivanib is being developed by Zai Lab Limited, which trades under the ticker ZLAB. Zai Lab is advancing the compound in oncology, with a development focus on hepatocellular carcinoma in Chinese patients.
Brivanib is in Phase 2 development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 program in hepatocellular carcinoma has been completed, and no trials of Brivanib are currently active.
Brivanib has been evaluated in the Phase 2 trial NCT03516071, titled A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC. That trial enrolled 90 patients in China, was controlled and randomized, and has been completed. No Brivanib trials are currently active.